SG160323A1 - Methods for controlling angiogenesis and cell proliferation - Google Patents

Methods for controlling angiogenesis and cell proliferation

Info

Publication number
SG160323A1
SG160323A1 SG200907751-2A SG2009077512A SG160323A1 SG 160323 A1 SG160323 A1 SG 160323A1 SG 2009077512 A SG2009077512 A SG 2009077512A SG 160323 A1 SG160323 A1 SG 160323A1
Authority
SG
Singapore
Prior art keywords
methods
cell proliferation
administering
angiogenesis
thrombin inhibitor
Prior art date
Application number
SG200907751-2A
Other languages
English (en)
Inventor
Cheng-Der Tony Yu
Original Assignee
Canyon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canyon Pharmaceuticals Inc filed Critical Canyon Pharmaceuticals Inc
Publication of SG160323A1 publication Critical patent/SG160323A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SG200907751-2A 2004-04-12 2005-04-05 Methods for controlling angiogenesis and cell proliferation SG160323A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56174104P 2004-04-12 2004-04-12

Publications (1)

Publication Number Publication Date
SG160323A1 true SG160323A1 (en) 2010-04-29

Family

ID=35150501

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200907751-2A SG160323A1 (en) 2004-04-12 2005-04-05 Methods for controlling angiogenesis and cell proliferation

Country Status (13)

Country Link
US (3) US7795205B2 (fr)
EP (1) EP1753291A4 (fr)
JP (1) JP2007532646A (fr)
AU (1) AU2005232625B2 (fr)
BR (1) BRPI0509876A (fr)
CA (1) CA2562756C (fr)
IL (1) IL178578A (fr)
MY (1) MY146091A (fr)
NZ (1) NZ551146A (fr)
SG (1) SG160323A1 (fr)
TW (1) TWI362941B (fr)
WO (1) WO2005099749A2 (fr)
ZA (1) ZA200609219B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795205B2 (en) * 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
ATE480561T1 (de) 2004-10-19 2010-09-15 Lonza Ag Verfahren zur festphasen-peptidsynthese
US20100239627A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Quarternary ammonium salts delivery systems
US20100239650A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Isothiazolin biodelivery systems
US20100239651A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Nitrilopropionamide delivery systems
US20100239626A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Propanediol delivery systems
US20100239630A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Phosphonium salts delivery systems
US7803762B1 (en) 2009-08-20 2010-09-28 The Medicines Company Ready-to-use bivalirudin compositions
US7985733B1 (en) 2010-01-06 2011-07-26 The Medicines Company Buffer-based method for preparing bivalirudin drug product
CN104906037A (zh) * 2015-06-23 2015-09-16 广西复鑫益生物科技有限公司平南分公司 一种重组水蛭素滴眼液及其制备方法
CN110404060A (zh) * 2018-04-28 2019-11-05 复旦大学 凝血酶抑制剂在制备抗肿瘤侵袭转移药物中的用途

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) * 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
CA1341414C (fr) * 1984-03-27 2002-12-31 Paul Tolstoshev Vecteurs d'expression de l'hirudine, cellules transformees et procede de preparation de l'hirudine
DE3438296A1 (de) 1984-04-18 1985-11-07 Hoechst Ag, 6230 Frankfurt Neue polypeptide mit blutgerinnungshemmender wirkung, verfahren zu deren herstellung bzw. gewinnung, deren verwendung und diese enthaltende mittel
EP0168342B1 (fr) 1984-06-14 1991-07-03 Ciba-Geigy Ag Procédé pour la préparation d'inhibiteurs de thrombine
DE3445532A1 (de) * 1984-12-13 1986-06-19 Plantorgan Werk Heinrich G.E. Christensen, KG, 2903 Bad Zwischenahn Hirudin-pa, desulfatohirudine-pa, verfahren zur herstellung und pharmazeutische mittel, die diese wirkstoffe enthalten
HU192646B (en) 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
AU600226B2 (en) 1985-02-04 1990-08-09 Merrell Pharmaceuticals Inc. Novel peptidase inhibitors
DE3738541A1 (de) 1987-11-13 1989-05-24 Hoechst Ag Verfahren zur isolierung und reinigung von hirudin
FR2593518B1 (fr) 1985-05-02 1989-09-08 Transgene Sa Vecteurs d'expression et de secretion de l'hirudine par les levures transformees
MY101203A (en) 1985-12-12 1991-08-17 Ucp Gen Pharma Ag Production of thrombin iinhibitors.
MC1834A1 (fr) 1986-07-10 1988-06-03 Transgene Sa Bloc fonctionnel d'adn et plasmide codant pour l'hirudine,levure transformee,procede de preparation de l'hirudine,hirudine obtenue et son utilisation
US5352664A (en) * 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
AU604925B2 (en) * 1988-02-23 1991-01-03 Schering Aktiengesellschaft A hirudin derivative
AU614121B2 (en) 1988-05-04 1991-08-22 Novartis Ag Improvements in the production of polypeptides
GB8817161D0 (en) 1988-07-19 1988-08-24 Ciba Geigy Ag Modified proteins
GB8817160D0 (en) 1988-07-19 1988-08-24 Ciba Geigy Ag Novel proteins
EP0362002B1 (fr) 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. Inhibiteurs de protease HIV
HUT55799A (en) * 1988-09-29 1991-06-28 Biogen Inc Process for producing hirudine-like peptides
ZA897514B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
FR2645175B1 (fr) * 1989-03-31 1994-02-18 Transgene Sa Souche de saccharomyces cerevisiaeproductrice d'une proteine heterologue et procede de preparation de ladite proteine heterologue par fermentation de ladite souche
US5096092A (en) * 1990-03-13 1992-03-17 Mmm, Ltd. Food dispensing apparatus utilizing inflatable bladder
TW201303B (fr) 1990-07-05 1993-03-01 Hoffmann La Roche
ES2129749T3 (es) * 1990-11-08 1999-06-16 Japan Energy Corp Vector de secrecion, microorganismos transformados que contienen el indicado vector y produccion de un producto a partir de dicho microorganismo.
DE4041185A1 (de) * 1990-12-21 1992-06-25 Knoll Ag Verwendung von hirudin und dessen muteinen zur kombinationsbehandlung von tumoren
AU659432B2 (en) 1991-03-08 1995-05-18 Novartis Ag A method for the inhibition or prevention of tumor cell metastasis with hirudin
CA2075154A1 (fr) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Aldehydes peptidiques utilises comme agents antithrombotiques
SE9102462D0 (sv) 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
CZ333492A3 (en) 1991-11-12 1993-09-15 Lilly Co Eli Dipeptide of l-azetidine-2-carboxylic acids and l-argininaldehyde, process of its preparation and pharmaceutical preparation in which said dipeptide is comprised
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
CA2131367A1 (fr) 1992-03-04 1993-09-16 Sandor Bajusz Nouveaux derives peptidiques anticoagulants et compositions pharmaceutiques en contenant; procede de fabrication
TW223629B (fr) 1992-03-06 1994-05-11 Hoffmann La Roche
SG49859A1 (en) * 1992-09-04 2002-03-19 Ucp Gen Pharma Ag Process for the production of protease inhibitors
AU675981B2 (en) 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
GB9303275D0 (en) * 1993-02-18 1993-04-07 Ciba Geigy Ag Pharmaceutical compositions
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
DE4321444A1 (de) * 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmazeutische Zubereitung
EP0648780A1 (fr) 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Inhibiteurs hétérocycliques de thrombine
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
GB9401448D0 (en) * 1994-01-26 1994-03-23 Ciba Geigy Ag Stable dry powders
GB9401447D0 (en) * 1994-01-26 1994-03-23 Ciba Geigy Ag Pharmaceutical compositions
AU1025795A (en) 1994-01-27 1995-08-03 Mitsubishi Chemical Corporation Prolineamide derivatives
ZA951617B (en) 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5561146A (en) 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (de) * 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
US5843925A (en) * 1994-12-13 1998-12-01 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
MX9706069A (es) 1995-02-17 1997-10-31 Basf Ag Nuevos inhibidores de la trombina.
SE9600216D0 (sv) * 1996-01-18 1996-01-18 Hans Arne Hansson Styrning av läkningsprocesser
AU736333B2 (en) * 1996-05-01 2001-07-26 Eli Lilly And Company Therapeutic treatment for VEGF related diseases
US6573256B2 (en) * 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
DE10033195A1 (de) * 2000-07-07 2002-03-21 Aventis Pharma Gmbh Bifunktionale Fusionsproteine aus Hirudin und TAP
US6696483B2 (en) * 2000-10-03 2004-02-24 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
US7795205B2 (en) * 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor

Also Published As

Publication number Publication date
BRPI0509876A (pt) 2007-10-16
CA2562756A1 (fr) 2005-10-27
AU2005232625A1 (en) 2005-10-27
TW200538466A (en) 2005-12-01
US20050233966A1 (en) 2005-10-20
IL178578A0 (en) 2007-02-11
WO2005099749A2 (fr) 2005-10-27
EP1753291A4 (fr) 2009-08-12
TWI362941B (en) 2012-05-01
CA2562756C (fr) 2011-08-23
ZA200609219B (en) 2012-02-29
WO2005099749A3 (fr) 2006-08-03
IL178578A (en) 2013-06-27
US20110224150A1 (en) 2011-09-15
AU2005232625B2 (en) 2011-07-28
US20090269422A1 (en) 2009-10-29
EP1753291A2 (fr) 2007-02-21
JP2007532646A (ja) 2007-11-15
US7795205B2 (en) 2010-09-14
MY146091A (en) 2012-06-29
NZ551146A (en) 2009-04-30

Similar Documents

Publication Publication Date Title
SG160323A1 (en) Methods for controlling angiogenesis and cell proliferation
TN2009000224A1 (en) Inhibitors of akt activity
WO2007062093A3 (fr) Polytherapie pour le traitement du cancer
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
WO2007058990A3 (fr) Therapie a base d’inhibiteurs de cytokine
WO2006091395A3 (fr) Inhibiteurs d'activite d'akt
MX2009012155A (es) Combinación farmacéutica sinérgica para el tratamiento de cáncer.
MX366119B (es) Uso de un agente inhibidor de masp-2 para el tratamiento de condiciones renales mediadas por complemento dependiente de la masp-2.
WO2006135627A3 (fr) Inhibiteurs de l'activite akt
WO2006110638A3 (fr) Inhibiteur de l'activite akt
SG178873A1 (en) Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
WO2005117954A3 (fr) Compositions et méthodes pour le traitement de maladies néovasculaires
MY148872A (en) Use of bifidobacterium longum for the prevention and treatment of inflammation
WO2007121088A3 (fr) Combinaisons d'agents thérapeutiques pour traiter un cancer
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
HK1162502A1 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3
WO2007123511A3 (fr) Schémas posologiques pour le traitement du cancer
AR062658A1 (es) Terapias de combinacion para artritis reumatoide
WO2006068796A3 (fr) Inhibiteurs de l'activite de akt
WO2008042480A3 (fr) Inhibiteurs époxyde de cystéine protéases
WO2008079270A3 (fr) Coadministration d'alpha-foetoprotéine et d'un agent immunomodulateur pour traiter la sclérose en plaques
MY148647A (en) Pharmaceutical compositions comprising a camtothecin derivative
WO2007130501A3 (fr) Polythérapie pour traiter le cancer
MX2008011454A (es) Uso novedoso de agentes antihistaminicos para el tratamiento preventivo o temprano de sindromes inflamatorios, en particular los que son accionados por togavirus.